Retatrutide
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Evidence sourceTrial registry · NCT04881760
Studied inAdults with obesity or overweight in a phase 2 trial; 338 enrolled
DesignRandomized trial with active and placebo arms
Human protocolNo general protocol established by this single study
What researchers measured
- Primary: mean percent change from baseline in body weight
- Secondary: proportions reaching source-defined body-weight reduction thresholds
Methods reported in this human study
- Placebo
- Matching placebo, subcutaneous, once weekly
- 1 mg
- 1 mg subcutaneous, once weekly
- 4 mg (2 mg start)
- 2 mg starting level, then 4 mg; subcutaneous, once weekly
- 4 mg
- 4 mg subcutaneous, once weekly
- 8 mg (2 mg start)
- 2 mg, then 4 mg, then 8 mg; subcutaneous, once weekly
- 8 mg (4 mg start)
- 4 mg starting level, then 8 mg; subcutaneous, once weekly
- 12 mg (2 mg start)
- 2 mg, then 4 mg, then 8 mg, then 12 mg; subcutaneous, once weekly
The registry lists starting and later dose levels, but its arm summaries do not specify every escalation date. Consult the original study and current registry record for full methods and results.
Open original source (NCT04881760) ↗
Search all original studies on Retatrutide → · Open Mix Chart →